Secondary prevention of coronary artery disease. :: University of Michigan Health System

GUIDELINE TITLE
University of Michigan Health System
Secondary prevention of coronary artery disease.

BIBLIOGRAPHIC SOURCE(S)
University of Michigan Health System. Secondary prevention of coronary artery disease. Ann Arbor (MI): University of Michigan Health System; 2009 Mar. 11 p. [36 references]

GUIDELINE STATUS
This is the current release of the guideline.

The University of Michigan Health System updated this guideline to include information on clopidogrel (Plavix) that was released after the publication of the March 29 version of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

March 12, 2010 - Plavix (clopidogrel): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients that a Boxed Warning has been added to the prescribing information for Plavix, an anti-blood clotting medication. The Boxed Warning includes information about reduced effectiveness in patients who are poor metabolizers of Plavix.
November 17, 2009 - Plavix (clopidogrel): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of new safety information concerning an interaction between clopidogrel (Plavix) and omeprazole (Prilosec/Prilosec OTC) used to reduce stomach acid. New data show that when clopidogrel and omeprazole are taken together, the effectiveness of clopidogrel is reduced.
July 1, 2009 - Chantix or Champix (Varenicline) and Zyban or Wellbutrin (bupropion or amfebutamone): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.

open here to see the full-text:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=16259&nbr=&string=